Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Orally Administered IPG1094 in Healthy Adult Participants

Next Previous
Trial Profile

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Orally Administered IPG1094 in Healthy Adult Participants

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IPG 1094 (Primary)
  • Indications Autoimmune disorders; Multiple myeloma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Nanjing Bioheng Biotech

Most Recent Events

  • 07 Dec 2021 According to Aimefei Pharmaceutical media release, since October this year, 22 healthy subjects have participated in the IPG1094 single-dose climbing test. Currently, the 600mg dose group of line 3 has been climbed without any drug-related adverse reactions, which proves that IPG1094 has good safety in this dose group sex.
  • 12 Nov 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top